X4 Pharmaceuticals/XFOR

$1.01

6.11%
-
1D1W1MYTD1YMAX

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery and development of therapies for people with diseases of the immune system. Its lead product candidate, mavorixafor, a small molecule antagonist of chemokine receptor C-X-C receptor type 4 (CXCR4), is being developed as an oral, once-daily therapy. Mavorixafor has the potential to provide therapeutic benefit across a variety of chronic neutropenic disorders, including warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a rare primary immunodeficiency. It also has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Ticker

XFOR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Paula Ragan

Employees

70

Headquarters

Boston, United States

XFOR Metrics

BasicAdvanced
$168.96M
Market cap
-
P/E ratio
-$0.79
EPS
0.44
Beta
-
Dividend rate

What the Analysts think about XFOR

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 7 analysts.
222.77% upside
High $5.00
Low $1.00
$1.01
Current price
$3.26
Average price target

XFOR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-2.3M
-95.87%
Profit margin
0%
-

XFOR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 93.28%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.29
-$0.16
-$0.33
-$0.01
-
Expected
-$0.24
-$0.22
-$0.16
-$0.15
-$0.15
Surprise
20.21%
-26.32%
102.04%
-93.28%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell X4 Pharmaceuticals stock

Buy or sell X4 Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing